25 related articles for article (PubMed ID: 2559738)
1. Pharmacological properties of the positive inotropic and alpha 1-adrenoceptor blocking agent saterinone.
Armah BI; Hofferber E; Stenzel W
Arzneimittelforschung; 1988 Sep; 38(9):1287-92. PubMed ID: 2906245
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
[TBL] [Abstract][Full Text] [Related]
3. Positive inotropic and vasodilatory actions of saterinone in vivo.
Armah BI; Hofferber E; Jacobitz P
Arzneimittelforschung; 1988 Sep; 38(9):1303-9. PubMed ID: 2906247
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiologic effects of saterinone and milrinone in the isolated guinea pig myocardium.
Iven H; Brasch H; Armah BI
Arzneimittelforschung; 1988 Sep; 38(9):1298-302. PubMed ID: 2906246
[TBL] [Abstract][Full Text] [Related]
5. Effects of saterinone and its enantiomers R(+)-saterinone and S(-)-saterinone on the phosphodiesterase isoenzymes from ventricular tissue of failing human hearts and porcine hearts.
Zimmermann W; Scholz H; Schumacher C; Wenzlaff H; Haverich A
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jun; 349(6):611-8. PubMed ID: 7526225
[TBL] [Abstract][Full Text] [Related]
6. Lack of stereoselectivity in the inotropic and phosphodiesterase inhibitory effects of saterinone enantiomers.
Armah BI; Muster D; Raap A; Brückner R; Graziadei I
Arzneimittelforschung; 1989 Nov; 39(11):1384-92. PubMed ID: 2559738
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase inhibition and Ca2+ sensitization.
Ravens U; Himmel HM; Flüss M; Davia K; Harding SE
Mol Cell Biochem; 1996 Apr 12-26; 157(1-2):245-9. PubMed ID: 8739254
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.
von der Leyen H
Klin Wochenschr; 1989 Jun; 67(12):605-15. PubMed ID: 2671473
[TBL] [Abstract][Full Text] [Related]
9. Enantiomers: implications and complications in developmental pharmacology.
Eichelbaum M
Dev Pharmacol Ther; 1992; 18(3-4):131-4. PubMed ID: 1306801
[TBL] [Abstract][Full Text] [Related]
10. New positive inotropic agents acting by phosphodiesterase inhibition or alpha 1-adrenergic stimulation.
von der Leyen H; Schmitz W; Scholz H; Scholz J
Pharmacol Res; 1989; 21(4):329-37. PubMed ID: 2570416
[TBL] [Abstract][Full Text] [Related]
11. Inotropic and vasopressor agents.
Smith LD; Oldershaw PJ
Br J Anaesth; 1984 Jul; 56(7):767-80. PubMed ID: 6375707
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
